Dr. Sulaiman Al Habib Medical Journal

<Previous Article In Issue
Next Article In Issue>
Volume 2, Issue 1, March 2020, Pages 4 - 9

Growth Hormone Therapy for Paediatric Growth Disorders: The Past, Present, and Future

Authors
Martin O. Savage1, *, Abdullah Alherbish2
1Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, UK
2Department of Paediatrics, Medical Administration, Al Habib Medical Group, Riyadh, Saudi Arabia
*Corresponding author. Email: m.o.savage@qmul.ac.uk
Corresponding Author
Martin O. Savage
Received 22 January 2020, Accepted 18 February 2020, Available Online 3 March 2020.
DOI
10.2991/dsahmj.k.200227.001How to use a DOI?
Keywords
Growth hormone therapy; pituitary; efficacy; safety
Abstract

Abnormal pituitary function was linked to excessive height and acromegaly in the late 19th century. Harvey Cushing proposed a pituitary substance that regulated human linear growth. Chemical characterization of the Growth Hormone (GH) molecule by Li led to a demonstration of its species specificity with only Human GH (hGH) stimulating growth in children. Extraction of hGH from cadaver pituitaries and its purification led to therapy by Raben in the 1950s, demonstrating growth acceleration in children with hypopituitarism. From the 1960s until 1985, pituitary-extracted hGH was used as therapy in GH-deficient children. In 1985, an epidemic of Creutzfeldt–Jakob disease, caused by contamination of pituitary-derived hGH with the prion protein, caused the deaths of more than 200 children worldwide. Cadaveric hGH was discontinued and replaced by Recombinant hGH (rhGH), which was licensed by the US Food and Drug Administration and European Medicines Agency for GH Deficiency (GHD), followed by non-GHD disorders, Turner syndrome, small for gestational age short stature, and idiopathic short stature. A mathematical model predicted human growth responses, but despite rhGH’s wide use and availability and good safety record, long-term responses remain variable. Poor adherence to rhGH has led to development of weekly or fortnightly hGH administration using different techniques to prolong activity. Data on tolerability, efficacy, and long-term safety of long-acting rhGH preparations will make up the next stage of the development of this important hormone therapy.

Copyright
© 2020 Dr. Sulaiman Al Habib Medical Group. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Dr. Sulaiman Al Habib Medical Journal
Volume-Issue
2 - 1
Pages
4 - 9
Publication Date
2020/03/03
ISSN (Online)
2590-3349
ISSN (Print)
2666-819X
DOI
10.2991/dsahmj.k.200227.001How to use a DOI?
Copyright
© 2020 Dr. Sulaiman Al Habib Medical Group. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Martin O. Savage
AU  - Abdullah Alherbish
PY  - 2020
DA  - 2020/03/03
TI  - Growth Hormone Therapy for Paediatric Growth Disorders: The Past, Present, and Future
JO  - Dr. Sulaiman Al Habib Medical Journal
SP  - 4
EP  - 9
VL  - 2
IS  - 1
SN  - 2590-3349
UR  - https://doi.org/10.2991/dsahmj.k.200227.001
DO  - 10.2991/dsahmj.k.200227.001
ID  - Savage2020
ER  -